Innospec Past Earnings Performance
Past criteria checks 4/6
Innospec has been growing earnings at an average annual rate of 11.8%, while the Chemicals industry saw earnings growing at 13% annually. Revenues have been growing at an average rate of 7.9% per year. Innospec's return on equity is 12.1%, and it has net margins of 7.1%.
Key information
11.8%
Earnings growth rate
11.4%
EPS growth rate
| Chemicals Industry Growth | 12.4% |
| Revenue growth rate | 7.9% |
| Return on equity | 12.1% |
| Net Margin | 7.1% |
| Next Earnings Update | 09 May 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Innospec makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 1,949 | 139 | 378 | 42 |
| 30 Sep 23 | 1,965 | 127 | 376 | 41 |
| 30 Jun 23 | 2,014 | 126 | 389 | 40 |
| 31 Mar 23 | 2,001 | 130 | 367 | 39 |
| 31 Dec 22 | 1,964 | 133 | 356 | 39 |
| 30 Sep 22 | 1,866 | 131 | 329 | 40 |
| 30 Jun 22 | 1,729 | 116 | 304 | 40 |
| 31 Mar 22 | 1,616 | 106 | 283 | 39 |
| 31 Dec 21 | 1,483 | 93 | 262 | 37 |
| 30 Sep 21 | 1,381 | 92 | 247 | 34 |
| 30 Jun 21 | 1,270 | 81 | 230 | 32 |
| 31 Mar 21 | 1,160 | 19 | 231 | 31 |
| 31 Dec 20 | 1,193 | 29 | 237 | 31 |
| 30 Sep 20 | 1,273 | 37 | 242 | 33 |
| 30 Jun 20 | 1,380 | 55 | 259 | 35 |
| 31 Mar 20 | 1,497 | 117 | 266 | 35 |
| 31 Dec 19 | 1,513 | 112 | 274 | 35 |
| 30 Sep 19 | 1,518 | 102 | 271 | 35 |
| 30 Jun 19 | 1,509 | 92 | 265 | 34 |
| 31 Mar 19 | 1,505 | 92 | 260 | 34 |
| 31 Dec 18 | 1,477 | 85 | 255 | 33 |
| 30 Sep 18 | 1,436 | 60 | 256 | 33 |
| 30 Jun 18 | 1,405 | 63 | 254 | 33 |
| 31 Mar 18 | 1,373 | 67 | 250 | 32 |
| 31 Dec 17 | 1,307 | 62 | 240 | 31 |
| 30 Sep 17 | 1,191 | 89 | 233 | 30 |
| 30 Jun 17 | 1,064 | 77 | 229 | 28 |
| 31 Mar 17 | 966 | 80 | 221 | 26 |
| 31 Dec 16 | 883 | 81 | 210 | 25 |
| 30 Sep 16 | 892 | 91 | 208 | 26 |
| 30 Jun 16 | 940 | 115 | 205 | 26 |
| 31 Mar 16 | 955 | 121 | 202 | 26 |
| 31 Dec 15 | 1,012 | 120 | 207 | 25 |
| 30 Sep 15 | 1,057 | 116 | 199 | 24 |
| 30 Jun 15 | 1,031 | 101 | 188 | 24 |
| 31 Mar 15 | 1,009 | 85 | 176 | 23 |
| 31 Dec 14 | 961 | 84 | 169 | 22 |
| 30 Sep 14 | 912 | 85 | 165 | 22 |
| 30 Jun 14 | 876 | 78 | 155 | 22 |
| 31 Mar 14 | 840 | 77 | 148 | 21 |
| 31 Dec 13 | 819 | 78 | 142 | 21 |
| 30 Sep 13 | 791 | 60 | 135 | 22 |
| 30 Jun 13 | 782 | 62 | 131 | 21 |
Quality Earnings: OCT has high quality earnings.
Growing Profit Margin: OCT's current net profit margins (7.1%) are higher than last year (6.8%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: OCT's earnings have grown by 11.8% per year over the past 5 years.
Accelerating Growth: OCT's earnings growth over the past year (4.6%) is below its 5-year average (11.8% per year).
Earnings vs Industry: OCT earnings growth over the past year (4.6%) exceeded the Chemicals industry -19.4%.
Return on Equity
High ROE: OCT's Return on Equity (12.1%) is considered low.